Special Issue "Angiogenesis Inhibitors"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 April 2011)
Prof. Dr. Domenico Ribatti (Website)
Dipartimento di Scienze Mediche di Base, Neuroscienze e Organi di Senso, Sezione di Anatomia Umana e Istologia, Piazza Giulio Cesare, 11 Policlinico, 70124 Bari, Italy
Fax: +39 080 5478310
Interests: role of FGF-2 and VEGF in the vascularization of the chick embryo chorioallantoic membrane; angiogenesis
The idea of targeting angiogenesis to inhibit tumor growth was proposed more than three decades ago by Judah Folkman, and since then several approaches to block or disrupt tumor angiogenesis have been explored.
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials.
Until now, the success of antiangiogenic compounds in the clinic is rather limited when given as monotherapies. This is in contrast with many preclinical results which revealed a much higher efficacy of these agents in animal models.
Prof. Dr. Domenico Ribatti
- angiopoietin-2 antagonists
- antiangiogenic monoclonal antibodies
- assays to validate antiangiogenic agents
- biomarkers of response to antiangiogenic therapy
- combination of antiangiogenic therapy with other anticancer therapies
- endogenous inhibitors of angiogenesis
- genetic strategies for targeting angiogenesis
- imaging of tumor angiogenesis
- integrins as targets for antiangiogenic therapy
- metronomic low-dose antiangiogenic chemotherapy
- protein tyrosine kinase inhibitors
- targeted drug delivery to the tumor neovasculature
- thalidomide and its IMiD derivatives
- translating angiogenesis inhibitors to the clinic